Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma.
The impact of pre-treatment maximum standardized uptake value (SUVmax) on the outcome following specific frontline regimens has not been explored. We performed a retrospective analysis of 346 patients with advanced stage FL without histological evidence of transformation, and analyzed the impact of SUVmax on outcome after frontline therapy. Fifty-two (15%) patients had a SUVmax > 18, and largest lymph node > 6 cm was the only factor associating with SUVmax > 18 on multivariate analysis (odds ratio 2.7, 95% confidence interval 1.3-5.3, p=0.006). The complete response rate was significantly lower among patients treated with non-anthracycline-based regimens if SUVmax was > 18 (45% vs 92%, p<0.001), but not among patients treated with R-CHOP (p=1). SUVmax > 18 was associated with significantly shorter progression-free survival among patients treated with non-anthracycline-based regimens (77 months vs not reached, p=0.02), but not among patients treated with R-CHOP (p=0.73). SUVmax > 18 associated with shorter overall survival (OS) both in patients treated with R-CHOP (8 year OS 70% vs 90%, p=0.02) and non-anthracycline-based frontline regimens (8 year OS 50% vs 85%, p=0.001). In conclusion, pre-treatment PET scan has prognostic and predictive value in patients with advanced stage FL receiving frontline treatment.